ASH Clinical News December 2016 | Page 29

• Advanced-stage Hodgkin lymphoma patients treated
with standard chemotherapy have poorer outcomes†3
— Stage I-II bulky (n = 268): 5-year FFS: 82%
— Stage III-IV (n = 525): 5-year FFS: 67%
• New frontline approaches are needed that add novel
agents targeting underlying drivers of disease to
standard chemotherapy4,5

FFS = failure-free survival.
*Up to 10% will not achieve complete remission, and 20%-30% of initial responders will relapse.2
†Results from a planned subgroup analysis of stage III-IV and stage I-II bulky Hodgkin lymphoma in a phase III trial evaluating ABVD vs Stanford V regimens
(study E2496). Failure-free survival was defined as the time from random assignment to progression, relapse, or death, whichever occurred first.3
References: 1. Hapgood G, et al. J Clin Oncol. 2016;34:2493-2500. 2. Kuruvilla J, et al. Blood. 2011;117:4208-4217. 3. Gordon LI, et al. J Clin Oncol.
2012;31:684-691. 4. Ansell SM. Mayo Clin Proc. 2015;90:1574-1583. 5. Matsuki E, Younes A. Semin Cancer Biol. 2015;34:14-21.
Seattle Genetics and its logo are US registered trademarks of Seattle Genetics, Inc.
© 2016 Seattle Genetics, Inc., Bothell, WA 98021
All rights reserved. Printed in USA USP-DIS-2016-0125(1) November 2016